The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > Physiogenex to present at the AASLD single topic conference on hepatic fibrosis in Dallas, TX, USA, Sept. 14-15th 2018

News detail

Return to all news & events

09/14/2018 Physiogenex to present at the AASLD single topic conference on hepatic fibrosis in Dallas, TX, USA, Sept. 14-15th 2018

Physiogenex will be presenting a study dealing with the effects of obeticholic acid and elafibranor in various animal models of NASH/hepatic fibrosis.
The study will be presented by Dr. François Briand, Director of Research and Business Development, during the poster session on Friday, September the 14th, from 11:45am to 1:15pm, poster #10.

If you wish to make an appointment during the meeting with Dr. François Briand to discuss about your drug development project, please contact us.